Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, February 15, 2025

Targeted codelivery of nitric oxide and hydrogen sulfide for enhanced antithrombosis efficacy

 Didn't your competent? doctor start working on protocols for these years ago? NO? So, you DON'T HAVE A FUNCTIONING STROKE DOCTOR, DO YOU?

  • hydrogen sulfide (13 posts to September 2012)
  • nitric oxide (117 posts to February 2013)

    • How about this?

    Smelling farts could be the best thing you do today

    Well, for your fart smelling needs there are still sales on eBay. What is your doctor's recommendation on this? 

    Targeted codelivery of nitric oxide and hydrogen sulfide for enhanced antithrombosis efficacy

    , ,
    https://doi.org/10.1016/j.bioactmat.2025.02.012
    Get rights and content
    Under a Creative Commons license
    open access

    Highlights

    • •
      We develope an enzyme‒prodrug system for the targeted codelivery of NO and H2S with reduced side effects caused by systemic delivery.
    • •
      Optimized combination of NO and H2S with a low combination index synergistically inhibitsplatelet adhesion and activation.
    • •
      Targeted codelivery of NO and H2S demonstrates enhanced therapeutic efficacy for thrombosis in two mousemodels of thrombosis.

    Abstract

    Thrombosis is a leading cause of mortality worldwide. As important gaseous signaling molecules, both nitric oxide (NO) and hydrogen sulfide (H2S) demonstrate antiplatelet and anticoagulant functions, but little attention has been given to their synergistic effect and the underlying mechanism. In the present study, we developed an NO/H2S codelivery system based on enzyme prodrug therapy (EPT) strategy in which the prodrugs are specifically recognized by the engineered β-galactosidase. Targeted codelivery of NO and H2S in vivo was demonstrated by near-infrared fluorescence imaging and confirmed by measuring plasma and tissue levels; as a result, the side effects caused by systemic delivery, such as bleeding time, were reduced. Delivery of an optimized combination of NO and H2S with a low combination index (CI) results in a synergistic effect on the inhibition of platelet adhesion and activation. Mechanistically, NO and H2S cooperatively enhance the cGMP level through redox-based posttranslational modifications of phosphodiesterase 5A (PDE5A), which leads to activation of the cGMP/PKG signaling pathway. Furthermore, targeted codelivery of NO and H2S demonstrates enhanced therapeutic efficacy for thrombosis in two mouse models of FeCl3-induced arterial thrombosis and deep vein thrombosis. Collectively, these results confirm the synergistic efficacy of NO and H2S for antithrombotic therapy, and the codelivery system developed in this study represents a promising candidate for clinical translation.
    Posted by at
    Labels: , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)